Robert Camp, PhD, MD

• Barbara Burtness
• Catherine Sullivan
• David F. Stern
• David Rimm
• Diane Kowalski
• Donald Lannin
• Harriet Kluger
• Herta Chao
• James Dziura
• John Wysolmerski
• Joshua VanHouten
• Lori Charette
• Lucia Jilaveanu
• Malini Harigopal
• Mario Sznol
• Robert Homer
• Ruth Halaban
• Sarah Weiss
• Shrikant Mane
• Yalai Bai

Data Interpretation, Statistical; Biomarkers; Automation, Laboratory

• Reliability of histopathologic diagnosis of fibrotic interstitial lung disease: an international collaborative standardization projectCamp R, Smith ML, Larsen BT, Roden AC, Farver C, Moreira AL, Attanoos R, Pillappa R, Sansano I, Fabro AT, Homer RJ. Reliability of histopathologic diagnosis of fibrotic interstitial lung disease: an international collaborative standardization project. BMC Pulmonary Medicine 2021, 21: 184. PMID: 34074264, PMCID: PMC8170950, DOI: 10.1186/s12890-021-01522-6.
• Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805Jilaveanu LB, Puligandla M, Weiss SA, Wang X, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical Cancer Research 2018, 24: 217-223. PMID: 29066509, PMCID: PMC5904512, DOI: 10.1158/1078-0432.ccr-17-1555.
• Staphylococcal Purpura FulminansHonarpisheh H, Camp R, Lazova R. Staphylococcal Purpura Fulminans. American Journal Of Dermatopathology 2015, 37: 643-646. PMID: 25099358, DOI: 10.1097/dad.0000000000000175.
• Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimensBaine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015, 6: 24990-25002. PMID: 26317902, PMCID: PMC4694809, DOI: 10.18632/oncotarget.4572.
• PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B. PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma? Journal Of Clinical Pathology 2014, 68: 12. PMID: 25315900, PMCID: PMC4429054, DOI: 10.1136/jclinpath-2014-202259.
• NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinomaGiesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. Oncotarget 2014, 5: 5209-5217. PMID: 24970819, PMCID: PMC4170640, DOI: 10.18632/oncotarget.2101.
• Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinomaAziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International 2014, 14: 4. PMID: 24423208, PMCID: PMC3896780, DOI: 10.1186/1475-2867-14-4.
• Expression of drug targets in primary and matched metastatic renal cell carcinoma tumorsAziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology 2013, 13: 3. PMID: 23374878, PMCID: PMC3575219, DOI: 10.1186/1472-6890-13-3.
• c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 343-349. PMID: 32018405, DOI: 10.1093/annonc/mds463.
• Vascularity of primary and metastatic renal cell carcinoma specimensAziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens. Journal Of Translational Medicine 2013, 11: 15. PMID: 23316728, PMCID: PMC3561185, DOI: 10.1186/1479-5876-11-15.
• c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaGibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology 2012, 24: 343-349. PMID: 23022995, PMCID: PMC3551486, DOI: 10.1093/annonc/mds463.
• Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancerAgarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Research 2012, 14: r124. PMID: 22971274, PMCID: PMC3962029, DOI: 10.1186/bcr3318.
• CD70 expression patterns in renal cell carcinomaJilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Human Pathology 2012, 43: 1394-1399. PMID: 22401771, PMCID: PMC3374042, DOI: 10.1016/j.humpath.2011.10.014.
• Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer CellsZito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH. Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells. PLOS ONE 2012, 7: e31331. PMID: 22355357, PMCID: PMC3280285, DOI: 10.1371/journal.pone.0031331.
• Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor OutcomeLazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome. Clinical Cancer Research 2012, 18: 370-379. PMID: 22080440, PMCID: PMC4825867, DOI: 10.1158/1078-0432.ccr-11-1282.
• Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohortsBaquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Research 2011, 13: r85. PMID: 21888627, PMCID: PMC3262195, DOI: 10.1186/bcr2937.
• Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast CancerChagpar AB, Camp RL, Rimm DL. Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer. Annals Of Surgical Oncology 2011, 18: 3143. PMID: 21847696, DOI: 10.1245/s10434-011-2012-9.
• Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variablesBai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Laboratory Investigation 2011, 91: 1253-1261. PMID: 21519325, PMCID: PMC3145004, DOI: 10.1038/labinvest.2011.75.
• Abstract 3786: LC3B-positive autophagosomes are a common feature of solid tumors and associated with proliferation, metastasis and poor outcomeLazova R, Camp R, Siddiqui S, Klump V, Pawelek J. Abstract 3786: LC3B-positive autophagosomes are a common feature of solid tumors and associated with proliferation, metastasis and poor outcome. Cancer Research 2011, 71: 3786-3786. DOI: 10.1158/1538-7445.am2011-3786.
• In vitro studies of dasatinib, its targets and predictors of sensitivityJilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell & Melanoma Research 2011, 24: 386-389. PMID: 21320292, PMCID: PMC4431976, DOI: 10.1111/j.1755-148x.2011.00835.x.
• C-met as a therapeutic target using ARQ 197 in renal cell carcinoma.Gibney G, Conrad P, Aziz S, Camp R, Schwartz B, Chen C, Kelly W, Kluger H. C-met as a therapeutic target using ARQ 197 in renal cell carcinoma. Journal Of Clinical Oncology 2011, 29: 360-360. DOI: 10.1200/jco.2011.29.7_suppl.360.
• Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating MelanomaAziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM. Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma. Clinical Cancer Research 2010, 16: 6029-6039. PMID: 21169255, PMCID: PMC3058635, DOI: 10.1158/1078-0432.ccr-10-1490.
• Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic modelsParisi F, González A, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research 2010, 12: r66. PMID: 20809974, PMCID: PMC3096952, DOI: 10.1186/bcr2633.
• Automated Analysis of Tissue MicroarraysDolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J. Automated Analysis of Tissue Microarrays. 2010, 664: 151-162. PMID: 20690061, DOI: 10.1007/978-1-60761-806-5_15.
• PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancerVanHouten J, Sullivan C, Bazinet C, Ryoo T, Camp R, Rimm DL, Chung G, Wysolmerski J. PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 11405-11410. PMID: 20534448, PMCID: PMC2895115, DOI: 10.1073/pnas.0911186107.
• Abstract 1753: High expression of the microtubule destabilizing protein stathmin is prognostic for worse outcome in breast cancerBaquero M, Hanna J, Agarwal S, Killiam E, Camp R, Rimm D. Abstract 1753: High expression of the microtubule destabilizing protein stathmin is prognostic for worse outcome in breast cancer. Cancer Research 2010, 70: 1753-1753. DOI: 10.1158/1538-7445.am10-1753.
• Abstract 1787: Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cellsChao H, Zito C, Jilaveanu L, Anagnostou V, Rimm D, Bepler G, Camp R, Kluger H. Abstract 1787: Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cells. Cancer Research 2010, 70: 1787-1787. DOI: 10.1158/1538-7445.am10-1787.
• Abstract 5106: Autophagy in malignant melanoma and breast carcinomaLazova R, Klump V, Siddiqui S, Camp R, Pawelek J. Abstract 5106: Autophagy in malignant melanoma and breast carcinoma. Cancer Research 2010, 70: 5106-5106. DOI: 10.1158/1538-7445.am10-5106.
• In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor PrognosisNeumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis. American Journal Of Pathology 2010, 176: 2131-2138. PMID: 20228222, PMCID: PMC2861079, DOI: 10.2353/ajpath.2010.090712.
• The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor developmentKidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, Boyce M, Modlin IM. The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Peptides 2010, 162: 52-60. PMID: 20144901, DOI: 10.1016/j.regpep.2010.01.009.
• Molecular Classification of Normal and Cancer Mammospheres.Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.
• Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysMehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Human Pathology 2009, 41: 375-384. PMID: 20004943, PMCID: PMC2824079, DOI: 10.1016/j.humpath.2009.08.016.
• Melanoma Prognostic Model Using Tissue Microarrays and Genetic AlgorithmsRothberg B, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL. Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms. Journal Of Clinical Oncology 2009, 27: 5772-5780. PMID: 19884546, PMCID: PMC2792999, DOI: 10.1200/jco.2009.22.8239.
• C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of MelanomasJilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas. Clinical Cancer Research 2009, 15: 5704-5713. PMID: 19737955, PMCID: PMC2763114, DOI: 10.1158/1078-0432.ccr-09-0198.
• Defining Molecular Phenotypes of Human Papillomavirus–Associated Oropharyngeal Squamous Cell CarcinomaWeinberger PM, Yu Z, Kountourakis P, Sasaki C, Haffty BG, Kowalski D, Merkley MA, Rimm DL, Camp RL, Psyrri A. Defining Molecular Phenotypes of Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma. Otolaryngology 2009, 141: 382-389. PMID: 19716018, DOI: 10.1016/j.otohns.2009.04.014.
• Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancerNadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Annals Of Oncology 2009, 21: 466-473. PMID: 19717535, PMCID: PMC2826097, DOI: 10.1093/annonc/mdp346.
• Construction of a five-marker protein-based model for stage-independent assessment of prognosis in breast cancerGiltnane J, Rapp J, Moeder C, Camp R, Kluger H, Molinaro A, Rimm D. Construction of a five-marker protein-based model for stage-independent assessment of prognosis in breast cancer. Journal Of Clinical Oncology 2009, 27: 11013-11013. DOI: 10.1200/jco.2009.27.15_suppl.11013.
• 44 High Efficacy of Gene Expression Profiling and Regularized Discriminant Analysis in the Prediction of Neuroendocrine Tumor Subtypes and Their MetastasesDrozdov I, Kidd M, Camp R, Mane S, Gustafsson B, Nadler B, Modlin I. 44 High Efficacy of Gene Expression Profiling and Regularized Discriminant Analysis in the Prediction of Neuroendocrine Tumor Subtypes and Their Metastases. Gastroenterology 2009, 136: a-7. DOI: 10.1016/s0016-5085(09)60034-2.
• Phosphatidylinositol-3-Kinase as a Therapeutic Target in MelanomaAziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. Clinical Cancer Research 2009, 15: 3029-3036. PMID: 19383818, PMCID: PMC4431617, DOI: 10.1158/1078-0432.ccr-08-2768.
• Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohortGiltnane JM, Moeder CB, Camp RL, Rimm DL. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009, 115: 2400-2409. PMID: 19330842, PMCID: PMC2756449, DOI: 10.1002/cncr.24277.
• Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learningDrozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, Gustafsson BI, Modlin IM. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 2009, 115: 1638-1650. PMID: 19197975, PMCID: PMC2743551, DOI: 10.1002/cncr.24180.
• Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and SorafenibJilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research 2009, 15: 1076-1085. PMID: 19188183, PMCID: PMC4263281, DOI: 10.1158/1078-0432.ccr-08-2280.
• Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney CancerLiu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T, Rzhetsky A, White KP. Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney Cancer. Science 2009, 323: 1218-1222. PMID: 19164706, PMCID: PMC2756524, DOI: 10.1126/science.1157669.
• In situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays.Neumeister V, Agarwal S, Camp R, Rimm D. In situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays. Cancer Research 2009, 69: 102. DOI: 10.1158/0008-5472.sabcs-102.
• Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysisKountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp RL, Diamandis EP, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis And Haemostasis 2009, 101: 541-546. PMID: 19277417, DOI: 10.1160/th08-01-0052.
• AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.Gustavson MD, Molinaro AM, Tedeschi G, Camp RL, Rimm DL. AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma. Archives Of Pathology & Laboratory Medicine 2008, 132: 1746-52. PMID: 18976010, DOI: 10.5858/132.11.1746.
• AQUA Analysis of Thymidylate Synthase Reveals Localization to be a Key Prognostic Biomarker in 2 Large Cohorts of Colorectal CarcinomaGustavson M, Molinaro A, Tedeschi G, Camp R, Rimm D. AQUA Analysis of Thymidylate Synthase Reveals Localization to be a Key Prognostic Biomarker in 2 Large Cohorts of Colorectal Carcinoma. Archives Of Pathology & Laboratory Medicine 2008, 132: 1746-1752. DOI: 10.5858/132.11.1746.
• A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer BiomarkersCamp RL, Neumeister V, Rimm DL. A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers. Journal Of Clinical Oncology 2008, 26: 5630-5637. PMID: 18936473, DOI: 10.1200/jco.2008.17.3567.
• Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, Diamandis EP, Dimopoulos MA. Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Science 2008, 99: 2224-2229. PMID: 18957059, DOI: 10.1111/j.1349-7006.2008.00942.x.
• Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancerSullivan CA, Ghosh S, Ocal IT, Camp RL, Rimm DL, Chung GG. Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer. Human Pathology 2008, 40: 156-165. PMID: 18799189, DOI: 10.1016/j.humpath.2008.07.005.
• High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancerGhosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Human Pathology 2008, 39: 1835-1843. PMID: 18715621, PMCID: PMC2632946, DOI: 10.1016/j.humpath.2008.06.004.
• Molecular Classification of HPV‐Associated Head Neck CancerWeinberger P, Yu Z, Kountourakis P, Sasaki C, Kowalski D, Rimm D, Camp R, Amanda P. Molecular Classification of HPV‐Associated Head Neck Cancer. Otolaryngology 2008, 139: p91-p91. DOI: 10.1016/j.otohns.2008.05.497.
• Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast CancerNadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer. Clinical Cancer Research 2008, 14: 4455-4462. PMID: 18628459, PMCID: PMC5849429, DOI: 10.1158/1078-0432.ccr-07-5268.
• Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cellsKluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Laboratory Investigation 2008, 88: 962-972. PMID: 18626467, DOI: 10.1038/labinvest.2008.65.
• Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcomeHarigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Research And Treatment 2008, 115: 77-85. PMID: 18521745, DOI: 10.1007/s10549-008-0063-9.
• Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancerNadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Research 2008, 10: r35. PMID: 18430249, PMCID: PMC2397537, DOI: 10.1186/bcr1998.
• Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expressionPsyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Diamandis E, Dimopoulos M, Kowalski D. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Annals Of Oncology 2008, 19: 1271-1277. PMID: 18325919, DOI: 10.1093/annonc/mdn035.
• Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of OutcomeMoeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL. Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome. Journal Of Clinical Oncology 2007, 25: 5418-5425. PMID: 18048824, DOI: 10.1200/jco.2007.12.8033.
• HSP90 as a marker of progression in melanomaMcCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, Rimm DL, Kluger HM. HSP90 as a marker of progression in melanoma. Annals Of Oncology 2007, 19: 590-594. PMID: 18037622, DOI: 10.1093/annonc/mdm545.
• Classification of renal cell carcinoma (RCC) based on the expression of VEGF and its receptors on tumor cells and microvessels: Identification of subsets with distinct patterns of expression, microvessel density, and outcomeCamp R, Siddiqui S, Kelly W, Uchio E, Kluger H. Classification of renal cell carcinoma (RCC) based on the expression of VEGF and its receptors on tumor cells and microvessels: Identification of subsets with distinct patterns of expression, microvessel density, and outcome. Journal Of Clinical Oncology 2007, 25: 15503-15503. DOI: 10.1200/jco.2007.25.18_suppl.15503.
• Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysisKountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp R, Diamandis E, Dimopoulos M. Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis. Journal Of Clinical Oncology 2007, 25: 5581-5581. DOI: 10.1200/jco.2007.25.18_suppl.5581.
• VEGF, VEGFR1, and VEGFR2 expression in melanomaMehnert J, McCarthy M, Aziz S, Sznol M, Flaherty K, Camp R, Rimm D, Kluger H. VEGF, VEGFR1, and VEGFR2 expression in melanoma. Journal Of Clinical Oncology 2007, 25: 8520-8520. DOI: 10.1200/jco.2007.25.18_suppl.8520.
• Assessment of PI3 kinase as a druggable target in melanomaAziz S, Pick-Golan E, McCarthy M, Flaherty K, Camp R, Rimm D, Kluger H. Assessment of PI3 kinase as a druggable target in melanoma. Journal Of Clinical Oncology 2007, 25: 8521-8521. DOI: 10.1200/jco.2007.25.18_suppl.8521.
• Bimodal Population or Pathologist Artifact?Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B. Bimodal Population or Pathologist Artifact? Journal Of Clinical Oncology 2007, 25: 2487-2488. PMID: 17557963, DOI: 10.1200/jco.2006.07.7537.
• Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor–β1‐mediated regulatory abnormalities including up‐regulation of C‐Myc and MTA1Kidd M, Modlin IM, Pfragner R, Eick GN, Champaneria MC, Chan AK, Camp RL, Mane SM. Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor–β1‐mediated regulatory abnormalities including up‐regulation of C‐Myc and MTA1. Cancer 2007, 109: 2420-2431. PMID: 17469181, DOI: 10.1002/cncr.22725.
• High HSP90 Expression Is Associated with Decreased Survival in Breast CancerPick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer. Cancer Research 2007, 67: 2932-2937. PMID: 17409397, DOI: 10.1158/0008-5472.can-06-4511.
• Quantitative analysis of estrogen receptor heterogeneity in breast cancerChung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Laboratory Investigation 2007, 87: 662-669. PMID: 17334408, DOI: 10.1038/labinvest.3700543.
• Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell CancerYu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 553-558. PMID: 17372251, DOI: 10.1158/1055-9965.epi-06-0121.
• Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a modelPozner-Moulis S, Cregger M, Camp RL, Rimm DL. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Laboratory Investigation 2007, 87: 251-260. PMID: 17260003, DOI: 10.1038/labinvest.3700515.
• The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitizationKluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. Journal Of Translational Medicine 2007, 5: 6. PMID: 17257402, PMCID: PMC1796544, DOI: 10.1186/1479-5876-5-6.
• Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsetsPsyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp R, Economopoulos T, Dimopoulos M. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Annals Of Oncology 2007, 18: 709-715. PMID: 17220511, DOI: 10.1093/annonc/mdl479.
• Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor OutcomeZerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.
• CTGF, intestinal stellate cells and carcinoid fibrogenesis.Kidd M, Modlin I, Shapiro M, Camp R, Mane S, Usinger W, Murren J. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World Journal Of Gastroenterology 2007, 13: 5208-16. PMID: 17876891, PMCID: PMC4171302, DOI: 10.3748/wjg.v13.i39.5208.
• Classification of Breast Cancer Using Genetic Algorithms and Tissue MicroarraysDolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research 2006, 12: 6459-6468. PMID: 17085660, DOI: 10.1158/1078-0432.ccr-06-1383.
• 326 POSTER Prognostic significance of human kallikrein 7 protein expression levels in ovarian cancer by using automated quantitative analysisKountourakis P, Psyrri A, Scorilas A, Kowalski D, Camp R, Markakis S, Dimopoulos M. 326 POSTER Prognostic significance of human kallikrein 7 protein expression levels in ovarian cancer by using automated quantitative analysis. European Journal Of Cancer Supplements 2006, 4: 102. DOI: 10.1016/s1359-6349(06)70331-7.
• Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with β-catenin levels and outcome in patients with epithelial ovarian cancerBamias A, Yu Z, Weinberger P, Markakis S, Kowalski D, Camp R, Rimm D, Dimopoulos M, Psyrri A. Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with β-catenin levels and outcome in patients with epithelial ovarian cancer. Annals Of Oncology 2006, 17: 1797-1802. PMID: 16971669, DOI: 10.1093/annonc/mdl310.
• Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid developmentKidd M, Modlin IM, Eick GN, Camp RL, Mane SM. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. AJP Gastrointestinal And Liver Physiology 2006, 292: g191-g200. PMID: 16950763, DOI: 10.1152/ajpgi.00131.2006.
• Genetic Differentiation of Appendiceal Tumor MalignancyModlin IM, Kidd M, Latich I, Zikusoka MN, Eick GN, Mane SM, Camp RL. Genetic Differentiation of Appendiceal Tumor Malignancy. Annals Of Surgery 2006, 244: 52-60. PMID: 16794389, PMCID: PMC1570599, DOI: 10.1097/01.sla.0000217617.06782.d5.
• Oropharyngeal squamous cell cancers (OSCC) bearing transcriptionally active human papillomavirus (HPV) display distinct protein expression profileWeinberger P, Kountourakis P, Sasaki C, Haffty B, Camp R, Rimm D, Psyrri A. Oropharyngeal squamous cell cancers (OSCC) bearing transcriptionally active human papillomavirus (HPV) display distinct protein expression profile. Journal Of Clinical Oncology 2006, 24: 10028-10028. DOI: 10.1200/jco.2006.24.18_suppl.10028.
• XIAP is highly expressed in melanoma and is associated with chemotherapy resistanceKluger H, McCarthy M, Alvero A, Divito K, Camp R, Rimm D, Mor G. XIAP is highly expressed in melanoma and is associated with chemotherapy resistance. Journal Of Clinical Oncology 2006, 24: 8008-8008. DOI: 10.1200/jco.2006.24.18_suppl.8008.
• Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in MelanomaMcCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma. Clinical Cancer Research 2006, 12: 3856-3863. PMID: 16778114, PMCID: PMC1839847, DOI: 10.1158/1078-0432.ccr-06-0190.
• Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein AnalysisPsyrri A, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1179-1183. PMID: 16775178, DOI: 10.1158/1055-9965.epi-06-0120.
• Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor OutcomeDolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome. Cancer Research 2006, 66: 5487-5494. PMID: 16707478, DOI: 10.1158/0008-5472.can-06-0100.
• Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarrayChung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray. Cancer 2006, 106: 1677-1684. PMID: 16532435, DOI: 10.1002/cncr.21783.
• Utility of molecular genetic signatures in the delineation of gastric neoplasiaKidd M, Modlin IM, Mane SM, Camp RL, Eick GN, Latich I, Zikusoka MN. Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer 2006, 106: 1480-1488. PMID: 16502410, DOI: 10.1002/cncr.21758.
• Q RT-PCR Detection of Chromogranin AKidd M, Modlin IM, Mane SM, Camp RL, Shapiro MD. Q RT-PCR Detection of Chromogranin A. Annals Of Surgery 2006, 243: 273-280. PMID: 16432362, PMCID: PMC1448909, DOI: 10.1097/01.sla.0000197734.28551.0f.
• The Role of Genetic Markers— NAP1L1, MAGE-D2, and MTA1—in Defining Small-Intestinal Carcinoid NeoplasiaKidd M, Modlin IM, Mane SM, Camp RL, Eick G, Latich I. The Role of Genetic Markers— NAP1L1, MAGE-D2, and MTA1—in Defining Small-Intestinal Carcinoid Neoplasia. Annals Of Surgical Oncology 2006, 13: 253-262. PMID: 16424981, DOI: 10.1245/aso.2006.12.011.
• Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable PrognosisWeinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis. Journal Of Clinical Oncology 2006, 24: 736-747. PMID: 16401683, DOI: 10.1200/jco.2004.00.3335.
• Computational Imaging, and Statistical Analysis of Tissue Microarrays: Quantitative Automated Analysis of Tissue MicroarraysBerger A, Camp R, Rimm D. Computational Imaging, and Statistical Analysis of Tissue Microarrays: Quantitative Automated Analysis of Tissue Microarrays. 2006, 381-403. DOI: 10.1007/0-387-26288-1_18.
• Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and PrognosisMcCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal Of The National Cancer Institute 2005, 97: 1808-1815. PMID: 16368942, DOI: 10.1093/jnci/dji427.
• Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian CancerPsyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8637-8643. PMID: 16361548, DOI: 10.1158/1078-0432.ccr-05-1436.
• Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian CancerPsyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8384-8390. PMID: 16322299, DOI: 10.1158/1078-0432.ccr-05-1270.
• Coexpression of β1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor OutcomeSiddiqui SF, Pawelek J, Handerson T, Lin CY, Dickson RB, Rimm DL, Camp RL. Coexpression of β1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome. Cancer Epidemiology Biomarkers & Prevention 2005, 14: 2517-2523. PMID: 16284372, DOI: 10.1158/1055-9965.epi-05-0464.
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative AnalysisPsyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research 2005, 11: 5856-5862. PMID: 16115926, DOI: 10.1158/1078-0432.ccr-05-0420.
• Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast CancerMcCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clinical Cancer Research 2005, 11: 5188-5194. PMID: 16033835, DOI: 10.1158/1078-0432.ccr-05-0158.
• Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive DiseaseKluger HM, Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease. Cancer Research 2005, 65: 5578-5587. PMID: 15994930, DOI: 10.1158/0008-5472.can-05-0108.
• Tissue microarrays – automated analysis and future directionsDiVito K, Camp R. Tissue microarrays – automated analysis and future directions. Breast Cancer Online 2005, 8 DOI: 10.1017/s1470903105003111.
• Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast CancerHarigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer. Clinical Cancer Research 2005, 11: 4083-4089. PMID: 15930343, DOI: 10.1158/1078-0432.ccr-04-2191.
• Analysis of epidermal growth factor receptor (EGFR) pathway in oropharyngeal squamous cell cancer patients in vivo (OSCC)Psyrri A, Yu Z, Haffty B, Sasaki C, Weinberger P, Camp R, Rimm D, Burtness B. Analysis of epidermal growth factor receptor (EGFR) pathway in oropharyngeal squamous cell cancer patients in vivo (OSCC). Journal Of Clinical Oncology 2005, 23: 5518-5518. DOI: 10.1200/jco.2005.23.16_suppl.5518.
• Molecular prognostic markers in oropharyngeal squamous cell carcinoma: The role of phospho-AktYu Z, Weinberger P, Sasaki C, Haffty B, Camp R, Rimm D, Burtness B, Psyrri A. Molecular prognostic markers in oropharyngeal squamous cell carcinoma: The role of phospho-Akt. Journal Of Clinical Oncology 2005, 23: 5517-5517. DOI: 10.1200/jco.2005.23.16_suppl.5517.
• High expression of the chemokine receptor CCR7 is associated with worse outcome in breast cancerAbu-Khalaf M, Wheler J, Zerkowski M, Camp R, Rimm D, Chung G. High expression of the chemokine receptor CCR7 is associated with worse outcome in breast cancer. Journal Of Clinical Oncology 2005, 23: 9593-9593. DOI: 10.1200/jco.2005.23.16_suppl.9593.
• In situ proteomics of biomarker expression in epithelial ovarian cancerKassar M, Yu Z, Bamias A, Markakis S, Kowalski D, Efstathiou E, Camp R, Rimm D, Psyrri D, Dimopoulos M. In situ proteomics of biomarker expression in epithelial ovarian cancer. Journal Of Clinical Oncology 2005, 23: 5041-5041. DOI: 10.1200/jco.2005.23.16_suppl.5041.
• Expression and prognostic value of TRAIL receptors R1 and R2 in early stage breast cancerMcCarthy M, Divito K, Camp R, Sznol M, Rimm D, Kluger H. Expression and prognostic value of TRAIL receptors R1 and R2 in early stage breast cancer. Journal Of Clinical Oncology 2005, 23: 9528-9528. DOI: 10.1200/jco.2005.23.16_suppl.9528.
• Quantitative image analysis of VEGF expression on a breast cancer tissue microarrayGhosh S, Zerkowski M, Abu-Khalaf M, Camp R, Rimm D, Chung G. Quantitative image analysis of VEGF expression on a breast cancer tissue microarray. Journal Of Clinical Oncology 2005, 23: 9534-9534. DOI: 10.1200/jco.2005.23.16_suppl.9534.
• β1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast CarcinomaHanderson T, Camp R, Harigopal M, Rimm D, Pawelek J. β1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma. Clinical Cancer Research 2005, 11: 2969-2973. PMID: 15837749, DOI: 10.1158/1078-0432.ccr-04-2211.
• β-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and NeckYu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. β-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and Neck. Clinical Cancer Research 2005, 11: 2471-2477. PMID: 15814622, DOI: 10.1158/1078-0432.ccr-04-2199.
• Cyclin D1 Is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell CarcinomaYu Z, Weinberger PM, Haffty BG, Sasaki C, Zerillo C, Joe J, Kowalski D, Dziura J, Camp RL, Rimm DL, Psyrri A. Cyclin D1 Is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research 2005, 11: 1160-1166. PMID: 15709184, DOI: 10.1158/1078-0432.1160.11.3.
• Microsatellite instability and gene mutations in transforming growth factor‐beta type II receptor are absent in small bowel carcinoid tumorsKidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor‐beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005, 103: 229-236. PMID: 15599934, DOI: 10.1002/cncr.20750.
• Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved OutcomeBerger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL. Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome. Cancer Research 2004, 64: 8767-8772. PMID: 15574789, DOI: 10.1158/0008-5472.can-04-1384.
• Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in MelanomaDivito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma. Cancer Research 2004, 64: 8773-8777. PMID: 15574790, DOI: 10.1158/0008-5472.can-04-1387.
• X-TileA New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point OptimizationCamp RL, Dolled-Filhart M, Rimm DL. X-TileA New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clinical Cancer Research 2004, 10: 7252-7259. PMID: 15534099, DOI: 10.1158/1078-0432.ccr-04-0713.
• 419 Automated quantitative in-situ method of protein analysis (AQUA) demonstrates that components of the retinoblastoma (Rb) pathway are potential molecular targets in oropharyngeal squamous cell cancerPsyrri A, Ziwei Y, Weinberger P, Haffty B, Sasaki C, Camp R, Rimm D. 419 Automated quantitative in-situ method of protein analysis (AQUA) demonstrates that components of the retinoblastoma (Rb) pathway are potential molecular targets in oropharyngeal squamous cell cancer. European Journal Of Cancer Supplements 2004, 2: 125-126. DOI: 10.1016/s1359-6349(04)80427-0.
• Long-term preservation of antigenicity on tissue microarraysDiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Laboratory Investigation 2004, 84: 1071-1078. PMID: 15195116, DOI: 10.1038/labinvest.3700131.
• Molecular prognostic markers in oropharyngeal squamous cell carcinoma; the role of C-metYu Z, Weinberger P, Kowalski D, Chang B, Sasaki C, Camp R, Haffty B, Rimm D, Psyrri A. Molecular prognostic markers in oropharyngeal squamous cell carcinoma; the role of C-met. Journal Of Clinical Oncology 2004, 22: 5517-5517. DOI: 10.1200/jco.2004.22.90140.5517.
• Molecular prognostic markers in oropharyngeal squamous cell carcinoma; the role of C-metYu Z, Weinberger P, Kowalski D, Chang B, Sasaki C, Camp R, Haffty B, Rimm D, Psyrri A. Molecular prognostic markers in oropharyngeal squamous cell carcinoma; the role of C-met. Journal Of Clinical Oncology 2004, 22: 5517-5517. DOI: 10.1200/jco.2004.22.14_suppl.5517.
• A possible association of human papilloma virus with a subset of colorectal adenocarcinomasWeinberger P, Yu Z, Zerkowski M, Chung G, Camp R, Rimm D, Psyrri A. A possible association of human papilloma virus with a subset of colorectal adenocarcinomas. Journal Of Clinical Oncology 2004, 22: 3544-3544. DOI: 10.1200/jco.2004.22.14_suppl.3544.
• Evaluation of Bcl-2 expression in melanoma - A tissue microarray studyDivito K, Dolled-Filhart M, Camp R, Berger A, Rimm D, Kluger H. Evaluation of Bcl-2 expression in melanoma - A tissue microarray study. Journal Of Clinical Oncology 2004, 22: 7515-7515. DOI: 10.1200/jco.2004.22.14_suppl.7515.
• A possible association of human papilloma virus with a subset of colorectal adenocarcinomasWeinberger P, Yu Z, Zerkowski M, Chung G, Camp R, Rimm D, Psyrri A. A possible association of human papilloma virus with a subset of colorectal adenocarcinomas. Journal Of Clinical Oncology 2004, 22: 3544-3544. DOI: 10.1200/jco.2004.22.90140.3544.
• Evaluation of Bcl-2 expression in melanoma - A tissue microarray studyDivito K, Dolled-Filhart M, Camp R, Berger A, Rimm D, Kluger H. Evaluation of Bcl-2 expression in melanoma - A tissue microarray study. Journal Of Clinical Oncology 2004, 22: 7515-7515. DOI: 10.1200/jco.2004.22.90140.7515.
• Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray studyKluger HM, DiVito K, Berger AJ, Halaban R, Ariyan S, Camp RL, Rimm DL. Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study. Melanoma Research 2004, 14: 207-210. PMID: 15179190, DOI: 10.1097/01.cmr.0000130874.33504.2f.
• β‐Catenin and p53 analyses of a breast carcinoma tissue microarrayChung GG, Zerkowski MP, Ocal IT, Dolled‐Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL. β‐Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004, 100: 2084-2092. PMID: 15139049, DOI: 10.1002/cncr.20232.
• Quantitative Determination of Expression of the Prostate Cancer Protein α-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA) A Novel Paradigm for Automated and Continuous Biomarker MeasurementsRubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, Rimm DL. Quantitative Determination of Expression of the Prostate Cancer Protein α-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA) A Novel Paradigm for Automated and Continuous Biomarker Measurements. American Journal Of Pathology 2004, 164: 831-840. PMID: 14982837, PMCID: PMC1613273, DOI: 10.1016/s0002-9440(10)63171-9.
• Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray AnalysisKluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis. Clinical Cancer Research 2004, 10: 173-177. PMID: 14734466, DOI: 10.1158/1078-0432.ccr-0699-3.
• ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal Of Clinical Oncology 2003, 21: 3226-35. PMID: 12947056, DOI: 10.1200/jco.2003.10.130.
• Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Research 2003, 63: 1445-8. PMID: 12670887.
• Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptorsOcal I, Dolled‐Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003, 97: 1841-1848. PMID: 12673709, DOI: 10.1002/cncr.11335.
• Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Research 2003, 63: 1101-5. PMID: 12615728.
• Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clinical Cancer Research 2003, 9: 594-600. PMID: 12576423.
• Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcomeKielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, Rimm DL. Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome. International Journal Of Cancer 2002, 103: 652-656. PMID: 12494474, DOI: 10.1002/ijc.10893.
• Automated subcellular localization and quantification of protein expression in tissue microarraysCamp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Medicine 2002, 8: 1323-1328. PMID: 12389040, DOI: 10.1038/nm791.
• Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Research 2002, 62: 497-505. PMID: 11809701.
• RET activation and clinicopathologic features in poorly differentiated thyroid tumors.Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 370-9. PMID: 11788678, DOI: 10.1210/jcem.87.1.8174.
• Amplification of Tissue by Construction of Tissue MicroarraysRimm D, Camp R, Charette L, Olsen D, Provost E. Amplification of Tissue by Construction of Tissue Microarrays. Experimental And Molecular Pathology 2001, 70: 255-264. PMID: 11418004, DOI: 10.1006/exmp.2001.2363.
• β-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor PrognosisGarcia-Rostan G, Camp R, Herrero A, Carcangiu M, Rimm D, Tallini G. β-Catenin Dysregulation in Thyroid Neoplasms Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis. American Journal Of Pathology 2001, 158: 987-996. PMID: 11238046, PMCID: PMC1850336, DOI: 10.1016/s0002-9440(10)64045-x.
• Tissue microarray: a new technology for amplification of tissue resources.Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. The Cancer Journal 2001, 7: 24-31. PMID: 11269645.
• Validation of Tissue Microarray Technology in Breast CarcinomaCamp R, Charette L, Rimm D. Validation of Tissue Microarray Technology in Breast Carcinoma. Laboratory Investigation 2000, 80: 1943-1949. PMID: 11140706, DOI: 10.1038/labinvest.3780204.
• Author replyCamp R, Rimm E, Rimm D. Author reply. Cancer 2000, 89: 218-219. PMID: 10897021, DOI: 10.1002/1097-0142(20000701)89:1<218::aid-cncr29>3.0.co;2-m.
• Aneurysmal bone cyst of the spine with familial incidence.DiCaprio MR, Murphy MJ, Camp RL. Aneurysmal bone cyst of the spine with familial incidence. Spine 2000, 25: 1589-92. PMID: 10851111, DOI: 10.1097/00007632-200006150-00021.
• A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcomeCamp R, Rimm E, Rimm D. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000, 88: 108-113. PMID: 10618612, DOI: 10.1002/(sici)1097-0142(20000101)88:1<108::aid-cncr15>3.0.co;2-b.
• Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinomaCamp R, Rimm E, Rimm D. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86: 2259-2265. PMID: 10590366, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2259::aid-cncr13>3.0.co;2-2.
• Unresponsiveness to 2,4-dinitro-1-fluoro-benzene after treatment with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1 during sensitization.Scheynius A, Camp RL, Puré E. Unresponsiveness to 2,4-dinitro-1-fluoro-benzene after treatment with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1 during sensitization. Journal Of Immunology (Baltimore, Md. : 1950) 1996, 156: 1804-9. PMID: 8596030.
• Defective phosphorylation and hyaluronate binding of CD44 with point mutations in the cytoplasmic domain.Puré E, Camp RL, Peritt D, Panettieri RA, Lazaar AL, Nayak S. Defective phosphorylation and hyaluronate binding of CD44 with point mutations in the cytoplasmic domain. The Journal Of Experimental Medicine 1995, 181: 55-62. PMID: 7528778, PMCID: PMC2191806, DOI: 10.1084/jem.181.1.55.
• CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation.Camp RL, Scheynius A, Johansson C, Puré E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. The Journal Of Experimental Medicine 1993, 178: 497-507. PMID: 8340756, PMCID: PMC2191099, DOI: 10.1084/jem.178.2.497.
• Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1.Scheynius A, Camp RL, Puré E. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. Journal Of Immunology (Baltimore, Md. : 1950) 1993, 150: 655-63. PMID: 8093459.
• Variations in the cytoskeletal interaction and posttranslational modification of the CD44 homing receptor in macrophages.Camp RL, Kraus TA, Puré E. Variations in the cytoskeletal interaction and posttranslational modification of the CD44 homing receptor in macrophages. The Journal Of Cell Biology 1991, 115: 1283-92. PMID: 1955476, PMCID: PMC2289237, DOI: 10.1083/jcb.115.5.1283.
• High levels of CD44 expression distinguish virgin from antigen-primed B cells.Camp RL, Kraus TA, Birkeland ML, Puré E. High levels of CD44 expression distinguish virgin from antigen-primed B cells. The Journal Of Experimental Medicine 1991, 173: 763-6. PMID: 1997654, PMCID: PMC2118816, DOI: 10.1084/jem.173.3.763.